Ye Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ye Cheng has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Jian-She Wang
The Center for Pediatric Liver Diseases, Children’s Hospital of Fudan University, Shanghai, China
4 shared publications - Qinghe Xing
Children’s Hospital of Fudan University and Institutes of Biomedical Sciences of Fudan University, Shanghai, China
3 shared publications - Changlian Zhu
Henan Key Laboratory of Child Brain Injury and Henan Pediatric Clinical Research Center, Institute of Neuroscience, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications Hongwei Li
Department of Pediatrics, Henan Key Laboratory of Child Brain Injury and Henan Pediatric Clinical Research Center, The Third Affiliated Hospital and Institute of Neuroscience of Zhengzhou University, Zhengzhou, China
2 shared publicationsJin Zhang
Children’s Hospital of Fudan University and Institutes of Biomedical Sciences of Fudan University, Shanghai, China
2 shared publications- Li Wang
The Center for Pediatric Liver Diseases, Children’s Hospital of Fudan University, Shanghai, China
2 shared publications
Latest Publications
- 19 March 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (5) , 1270-1285
Liver transcriptome sequencing contributes to the molecular diagnosis of genetic liver diseases
Background & Aims: Since DNA sequencing alone faces challenges in variant interpretation during genetic diagnosis, RNA sequencing has recently gained attention in resolving these diagnostic gaps. This study aimed to evaluate the advantages of liver tissue RNA sequencing in the diagnosis of genetic liver diseases. Approach & Result: Liver tissue RNA sequencing was performed on 147 patients with prior DNA sequencing. We evaluated the role of RNA sequencing by analyzing aberrant gene expression, splicing, allele-specific expression, transcript-level similarity and mosaic variants. Liver RNA-seq supported the molecular diagnoses in 56 patients diagnosed by DNA sequencing alone. Among 91 previously undiagnosed patients, incorporating RNA sequencing established a diagnosis in 17 (18.68%) patients. Among the 33 patients with indicative clinical phenotypes or prioritized variants, diagnosis was established in 15 (45.45%) patients under the help of RNA sequencing. This improvement was primarily (16/17) driven by the detection of aberrant splicing and allele-specific expression, instead of aberrant expression. RNA sequencing revealed ±50bp of cryptic splicing sites as hotspot regions, characterized allele-specific expression at both the gene and variant levels and revealed shared transcriptomic features in low GGT cholestasis. Conclusions: While DNA sequencing demonstrates superior sensitivity in detecting clinically relevant variants, liver RNA sequencing significantly enhances genetic diagnosis mainly by revealing aberrant splicing and allele-specific expression. These findings suggest that RNA sequencing is an essential complement to DNA sequencing. Export
- 19 March 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (5) , 1270-1285
Liver transcriptome sequencing contributes to the molecular diagnosis of genetic liver diseases
Background & Aims: Since DNA sequencing alone faces challenges in variant interpretation during genetic diagnosis, RNA sequencing has recently gained attention in resolving these diagnostic gaps. This study aimed to evaluate the advantages of liver tissue RNA sequencing in the diagnosis of genetic liver diseases. Approach & Result: Liver tissue RNA sequencing was performed on 147 patients with prior DNA sequencing. We evaluated the role of RNA sequencing by analyzing aberrant gene expression, splicing, allele-specific expression, transcript-level similarity and mosaic variants. Liver RNA-seq supported the molecular diagnoses in 56 patients diagnosed by DNA sequencing alone. Among 91 previously undiagnosed patients, incorporating RNA sequencing established a diagnosis in 17 (18.68%) patients. Among the 33 patients with indicative clinical phenotypes or prioritized variants, diagnosis was established in 15 (45.45%) patients under the help of RNA sequencing. This improvement was primarily (16/17) driven by the detection of aberrant splicing and allele-specific expression, instead of aberrant expression. RNA sequencing revealed ±50bp of cryptic splicing sites as hotspot regions, characterized allele-specific expression at both the gene and variant levels and revealed shared transcriptomic features in low GGT cholestasis. Conclusions: While DNA sequencing demonstrates superior sensitivity in detecting clinically relevant variants, liver RNA sequencing significantly enhances genetic diagnosis mainly by revealing aberrant splicing and allele-specific expression. These findings suggest that RNA sequencing is an essential complement to DNA sequencing. Export
- Top Cited Papers
- 1 May 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (5) , 1395-1405
Exome sequencing reveals genetic heterogeneity and clinically actionable findings in children with cerebral palsy
Cerebral palsy (CP) is the most common motor disability in children. To ascertain the role of major genetic variants in the etiology of CP, we conducted exome sequencing on a large-scale cohort with clinical manifestations of CP. The study cohort comprised 505 girls and 1,073 boys. Utilizing the current gold standard in genetic diagnostics, 387 of these 1,578 children (24.5%) received genetic diagnoses. We identified 412 pathogenic and likely pathogenic (P/LP) variants across 219 genes associated with neurodevelopmental disorders, and 59 P/LP copy number variants. The genetic diagnostic rate of children with CP labeled at birth with perinatal asphyxia was higher than the rate in children without asphyxia (P = 0.0033). Also, 33 children with CP manifestations (8.5%, 33 of 387) had findings that were clinically actionable. These results highlight the need for early genetic testing in children with CP, especially those with risk factors like perinatal asphyxia, to enable evidence-based medical decision-making.
- 1 May 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (5) , 1395-1405
Top Cited PapersExome sequencing reveals genetic heterogeneity and clinically actionable findings in children with cerebral palsy
Cerebral palsy (CP) is the most common motor disability in children. To ascertain the role of major genetic variants in the etiology of CP, we conducted exome sequencing on a large-scale cohort with clinical manifestations of CP. The study cohort comprised 505 girls and 1,073 boys. Utilizing the current gold standard in genetic diagnostics, 387 of these 1,578 children (24.5%) received genetic diagnoses. We identified 412 pathogenic and likely pathogenic (P/LP) variants across 219 genes associated with neurodevelopmental disorders, and 59 P/LP copy number variants. The genetic diagnostic rate of children with CP labeled at birth with perinatal asphyxia was higher than the rate in children without asphyxia (P = 0.0033). Also, 33 children with CP manifestations (8.5%, 33 of 387) had findings that were clinically actionable. These results highlight the need for early genetic testing in children with CP, especially those with risk factors like perinatal asphyxia, to enable evidence-based medical decision-making.
- Open Access
- 22 December 2023
- Published by Oxford University Press (OUP) in Gastroenterology Report
- Vol. 12, goad073
Transcript selection for the genetic diagnosis of KIF12-associated progressive familial intrahepatic cholestasis
Cholestatic jaundice in infancy occurs in ∼1 in 2,500 term infants and 25% of cases are genetically determined [ 1]. An accurate diagnosis is crucial for clinicians to provide timely and personalized management. Despite the increasing application of whole-exome sequencing (WES), the genetic diagnosis of some patients remains unclear.
- 22 December 2023
- Published by Oxford University Press (OUP) in Gastroenterology Report
- Vol. 12, goad073
Open AccessTranscript selection for the genetic diagnosis of KIF12-associated progressive familial intrahepatic cholestasis
Cholestatic jaundice in infancy occurs in ∼1 in 2,500 term infants and 25% of cases are genetically determined [ 1]. An accurate diagnosis is crucial for clinicians to provide timely and personalized management. Despite the increasing application of whole-exome sequencing (WES), the genetic diagnosis of some patients remains unclear.
- Open Access
- 27 July 2023
- Published by Wiley in Human Mutation
- Vol. 2023, 1-12
Splicing Analysis of MYO5B Noncanonical Variants in Patients with Low Gamma-Glutamyltransferase Cholestasis
Biallelic MYO5B variants have been associated with familial intrahepatic cholestasis (FIC) with low serum gamma-glutamyltransferase (GGT). Intronic or synonymous variants outside of canonical splice sites (hereinafter referred to as noncanonical variants) with uncertain significance were identified in MYO5B posing a challenge in clinical interpretation. This study is aimed at assessing the effects of these variants on premessenger RNA (pre-mRNA) splicing to improve recognition of pathogenic spliceogenic variants in MYO5B and better characterize the MYO5B genetic variation spectrum. Disease-associated MYO5B noncanonical variants were collected from the literature or newly identified low GGT cholestasis patients. In silico splicing predictions were performed to prioritize potential pathogenic variants. Minigene splicing assays were performed to determine their splicing patterns, with confirmation by blood RNA analysis in one case. Eleven (five novel) noncanonical variants with uncertain significance were identified. Minigene splicing assays revealed that three variants (c.2090+3AT, c.2414+5GT, and c.613-11GA) caused complete aberrations, five variants (c.2349AG/p.(=), c.4221GA/p.(=), c.1322+5GA, c.1669-35AC, and c.3045+3AT) caused predominant aberrations, and three variants (c.4852+11AG, c.455+8TC, and c.2415-6CG) had no effect on pre-mRNA splicing. Patient-derived RNA analysis showed consistent results. Based on our results, eight variants were reclassified as likely pathogenic and three as likely benign. Combining the clinical features and the above analysis, the diagnosis of MYO5B-associated FIC could be made in three new patients. In conclusion, we characterized the splicing patterns of MYO5B noncanonical variants and suggest that RNA analysis should be routinely included in clinical diagnostics to provide essential evidence for the interpretation of variants.
- 27 July 2023
- Published by Wiley in Human Mutation
- Vol. 2023, 1-12
Open AccessSplicing Analysis of MYO5B Noncanonical Variants in Patients with Low Gamma-Glutamyltransferase Cholestasis
Biallelic MYO5B variants have been associated with familial intrahepatic cholestasis (FIC) with low serum gamma-glutamyltransferase (GGT). Intronic or synonymous variants outside of canonical splice sites (hereinafter referred to as noncanonical variants) with uncertain significance were identified in MYO5B posing a challenge in clinical interpretation. This study is aimed at assessing the effects of these variants on premessenger RNA (pre-mRNA) splicing to improve recognition of pathogenic spliceogenic variants in MYO5B and better characterize the MYO5B genetic variation spectrum. Disease-associated MYO5B noncanonical variants were collected from the literature or newly identified low GGT cholestasis patients. In silico splicing predictions were performed to prioritize potential pathogenic variants. Minigene splicing assays were performed to determine their splicing patterns, with confirmation by blood RNA analysis in one case. Eleven (five novel) noncanonical variants with uncertain significance were identified. Minigene splicing assays revealed that three variants (c.2090+3AT, c.2414+5GT, and c.613-11GA) caused complete aberrations, five variants (c.2349AG/p.(=), c.4221GA/p.(=), c.1322+5GA, c.1669-35AC, and c.3045+3AT) caused predominant aberrations, and three variants (c.4852+11AG, c.455+8TC, and c.2415-6CG) had no effect on pre-mRNA splicing. Patient-derived RNA analysis showed consistent results. Based on our results, eight variants were reclassified as likely pathogenic and three as likely benign. Combining the clinical features and the above analysis, the diagnosis of MYO5B-associated FIC could be made in three new patients. In conclusion, we characterized the splicing patterns of MYO5B noncanonical variants and suggest that RNA analysis should be routinely included in clinical diagnostics to provide essential evidence for the interpretation of variants.
- 3 February 2023
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 25 (4) , 227-233
Recurrent AKR1D1 c.580-13T>A Variant
- 3 February 2023
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 25 (4) , 227-233
Recurrent AKR1D1 c.580-13T>A Variant
- Open Access
- 14 December 2022
- Published by Springer Nature in Research Square
Exome-wide association study identified genetic variants contributing to the risk of cerebral palsy
Cerebral palsy (CP) is the most common physical disability in childhood that results from the interaction of environmental and genetic factors. Yet in many patients, the etiology remains unknown. We identified significant association at rs3131787 within the human leukocyte antigen (HLA) region using two-stage association study between 1,090 CP cases and 1,100 controls. Fine mapping of the HLA region indicated that the carrier frequency of HLA-B*13:02 was significantly higher in CP, particularly in CP without preterm birth, low birth weight, birth asphyxia or periventricular leukomalacia (PVL). DRB1*07:01/DQA1*02:01 was also significantly enriched in CP and more specifically in dyskinetic type. Additionally, significant enrichment of carrier frequency was detected for HLA-A*32:01 in CP with either preterm birth or low birth weight and for HLA-B*27:05 in CP with birth asphyxia. These data suggest that immune dysregulation resulting from immunogenetic variants or environmental exposures may underlie the pathogenesis of CP.
- 14 December 2022
- Published by Springer Nature in Research Square
Open AccessExome-wide association study identified genetic variants contributing to the risk of cerebral palsy
Cerebral palsy (CP) is the most common physical disability in childhood that results from the interaction of environmental and genetic factors. Yet in many patients, the etiology remains unknown. We identified significant association at rs3131787 within the human leukocyte antigen (HLA) region using two-stage association study between 1,090 CP cases and 1,100 controls. Fine mapping of the HLA region indicated that the carrier frequency of HLA-B*13:02 was significantly higher in CP, particularly in CP without preterm birth, low birth weight, birth asphyxia or periventricular leukomalacia (PVL). DRB1*07:01/DQA1*02:01 was also significantly enriched in CP and more specifically in dyskinetic type. Additionally, significant enrichment of carrier frequency was detected for HLA-A*32:01 in CP with either preterm birth or low birth weight and for HLA-B*27:05 in CP with birth asphyxia. These data suggest that immune dysregulation resulting from immunogenetic variants or environmental exposures may underlie the pathogenesis of CP.